|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Amgen |
|---|---|
| Information provided by: | Amgen |
| ClinicalTrials.gov Identifier: | NCT00037518 |
Purpose
This study will assess an investigational medication for patients with severe primary hyperparathyroidism or parathyroid cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Hyperparathyroidism Parathyroid Neoplasms |
Drug: AMG 073 |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism. |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Contacts and Locations
More Information
| Responsible Party: | Amgen Inc. ( Global Development Leader ) |
| Study ID Numbers: | 20000204 |
| Study First Received: | May 17, 2002 |
| Last Updated: | November 12, 2009 |
| ClinicalTrials.gov Identifier: | NCT00037518 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Severe primary hyperparathyroidism Parathyroid carcinoma |
|
Parathyroid Diseases Parathyroid Neoplasms Neoplasms Neoplasms by Site Hyperparathyroidism |
Head and Neck Neoplasms Endocrine System Diseases Hyperparathyroidism, Primary Endocrine Gland Neoplasms |